Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455975 · ClinicalTrials.gov registry record · Phase 2
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
A Phase 2 study of Kidney Cancer and Renal Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
- 13
- Study locations
NCT00455975: Completed Phase 2 study of Kidney Cancer and Renal Cancer, sponsored by SCRI Development Innovations.
NCT00455975 is a Phase 2 study of Kidney Cancer and Renal Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 119 participants, below the 878-participant average among 60 other Kidney Cancer trials with a reported enrollment target (86% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00455975, a Phase 2 study of Kidney Cancer and Renal Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
- 13
- Study locations
Study Summary
This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.
Primary Outcome
Progression-free survival is measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death on study. Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Conditions Studied
Interventions
- DRUG Bevacizumab
Study Locations (13)
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Family Cancer Center - Collierville
- Tennessee Oncology, PLLC - Nashville
Florida
- Florida Cancer Specialists - Fort Myers
Georgia
- Northeast Georgia Medical Center - Gainesville
Kentucky
- Consultants in Blood Disorders and Cancer - Louisville
Maryland
- Center for Cancer and Blood Disorders - Bethesda
Nebraska
- Methodist Cancer Center - Omaha
North Carolina
- Cancer Care of Western North Carolina - Asheville
Ohio
- Oncology Hematology Care - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT00455975 record still lists
NCT00455975 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 878-participant average among 60 other Kidney Cancer trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.
NCT00455975 lists 13 locations in 11 states (Tennessee, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT00455975 about?
NCT00455975 is a clinical study titled "High-dose Bevacizumab in Advanced Renal Carcinoma Patients". This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.
What is the current status of trial NCT00455975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2007-02. Estimated completion is 2013-09.
What conditions does trial NCT00455975 study?
This clinical trial studies the following conditions: Kidney Cancer, Renal Cancer.
What interventions are being tested in trial NCT00455975?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00455975?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00455975 being conducted?
This trial has 13 study locations across Florida, Georgia, Kentucky, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00455975's enrollment target sits among peer trials
119 23rd of 60 higher than 38 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia